Suppr超能文献

阿尔茨海默病:草药药物的分子方面和治疗机会。

Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.

机构信息

Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, Haryana, India.

Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, Haryana, India.

出版信息

Ageing Res Rev. 2023 Jul;88:101960. doi: 10.1016/j.arr.2023.101960. Epub 2023 May 22.

Abstract

Alzheimer's disease (AD), also called senile dementia, is the most common neurological disorder. Around 50 million people, mostly of advanced age, are suffering from dementia worldwide and this is expected to reach 100-130 million between 2040 and 2050. AD is characterized by impaired glutamatergic and cholinergic neurotransmission, which is associated with clinical and pathological symptoms. AD is characterized clinically by loss of cognition and memory impairment and pathologically by senile plaques formed by Amyloid β deposits or neurofibrillary tangles (NFT) consisting of aggregated tau proteins. Amyloid β deposits are responsible for glutamatergic dysfunction that develops NMDA dependent Ca influx into postsynaptic neurons generating slow excitotoxicity process leading to oxidative stress and finally impaired cognition and neuronal loss. Amyloid decreases acetylcholine release, synthesis and neuronal transport. The decreased levels of neurotransmitter acetylcholine, neuronal loss, tau aggregation, amyloid β plaques, increased oxidative stress, neuroinflammation, bio-metal dyshomeostasis, autophagy, cell cycle dysregulation, mitochondrial dysfunction, and endoplasmic reticulum dysfunction are the factors responsible for the pathogenesis of AD. Acetylcholinesterase, NMDA, Glutamate, BACE1, 5HT6, and RAGE (Receptors for Advanced Glycation End products) are receptors targeted in treatment of AD. The FDA approved acetylcholinesterase inhibitors Donepezil, Galantamine and Rivastigmine and N-methyl-D-aspartate antagonist Memantine provide symptomatic relief. Different therapies such as amyloid β therapies, tau-based therapies, neurotransmitter-based therapies, autophagy-based therapies, multi-target therapeutic strategies, and gene therapy modify the natural course of the disease. Herbal and food intake is also important as preventive strategy and recently focus has also been placed on herbal drugs for treatment. This review focuses on the molecular aspects, pathogenesis and recent studies that signifies the potential of medicinal plants and their extracts or chemical constituents for the treatment of degenerative symptoms related to AD.

摘要

阿尔茨海默病(AD),又称老年性痴呆,是最常见的神经退行性疾病。目前全世界约有 5000 万人患有痴呆症,其中大多数为老年人,预计到 2040 年至 2050 年,这一数字将达到 1 亿至 1.3 亿。AD 的特征是谷氨酸能和胆碱能神经传递受损,这与临床和病理症状有关。AD 临床上表现为认知功能丧失和记忆障碍,病理学上表现为由β淀粉样蛋白沉积形成的老年斑或由聚集的 tau 蛋白组成的神经原纤维缠结(NFT)。β淀粉样蛋白沉积负责谷氨酸能功能障碍,发展为 NMDA 依赖性 Ca 内流入突触后神经元,产生缓慢的兴奋性毒性过程,导致氧化应激,最终导致认知障碍和神经元丧失。β淀粉样蛋白降低乙酰胆碱的释放、合成和神经元运输。神经递质乙酰胆碱水平降低、神经元丧失、tau 聚集、β淀粉样蛋白斑块形成、氧化应激增加、神经炎症、生物金属动态失衡、自噬、细胞周期失调、线粒体功能障碍和内质网功能障碍是 AD 发病机制的原因。乙酰胆碱酯酶、NMDA、谷氨酸、BACE1、5HT6 和 RAGE(晚期糖基化终产物受体)是 AD 治疗的靶点。FDA 批准的乙酰胆碱酯酶抑制剂多奈哌齐、加兰他敏和利伐斯的明和 N-甲基-D-天冬氨酸拮抗剂美金刚可提供症状缓解。不同的治疗方法,如β淀粉样蛋白疗法、tau 疗法、神经递质疗法、自噬疗法、多靶点治疗策略和基因治疗,可改变疾病的自然进程。草药和食物摄入也是预防策略的重要组成部分,最近人们也开始关注草药药物治疗。本文综述了 AD 的分子方面、发病机制和最新研究,这些研究表明了药用植物及其提取物或化学成分治疗 AD 相关退行性症状的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验